We have located links that may give you full text access.
The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study.
Journal of Rheumatology 1999 June
OBJECTIVE: To examine patients presenting with polymyalgia rheumatica (PMR) during a 10 year period in Northwestern Spain and to assess disease incidence and the frequency of relapses in patients diagnosed as having either isolated ("pure") PMR or PMR associated with giant cell arteritis (GCA).
METHODS: Clinical records of patients with PMR diagnosed at the Hospital Xeral Lugo from January 1987 through December 1996 were reviewed. Patients with PMR were categorized into 2 subgroups depending on the presence or absence of associated GCA. Other conditions presenting with polymyalgia symptoms or mimicking isolated PMR were excluded. These patients were followed from the time of diagnosis until either patient's death or January 1, 1998.
RESULTS: One hundred eighty-five patients were studied. The average annual incidence rates of the total group of PMR and isolated PMR were 18.67 x 10(-5) and 13.52 x 10(-5), respectively, in a population aged 50 years or older. Relapses were frequent in both isolated PMR and PMR associated with GCA. In general, they occurred when the dose of prednisone was < 7.5 mg/day or it had been discontinued. Rate of steroid tapering was significantly higher in patients with isolated PMR who had relapses. Patients with HLA-DRB1*0401 had a higher frequency of relapses. As reported in patients with PMR associated with GCA, the adjusted mortality rate in patients with isolated PMR showed no difference compared to the Spanish population aged 50 years or older.
CONCLUSION: In Northwestern Spain, PMR is a nonfatal disease with a low incidence and frequent relapses. A possible influence of HLA-DRB1*04 alleles in the development of more severe disease, with greater tendency to relapses, is suggested.
METHODS: Clinical records of patients with PMR diagnosed at the Hospital Xeral Lugo from January 1987 through December 1996 were reviewed. Patients with PMR were categorized into 2 subgroups depending on the presence or absence of associated GCA. Other conditions presenting with polymyalgia symptoms or mimicking isolated PMR were excluded. These patients were followed from the time of diagnosis until either patient's death or January 1, 1998.
RESULTS: One hundred eighty-five patients were studied. The average annual incidence rates of the total group of PMR and isolated PMR were 18.67 x 10(-5) and 13.52 x 10(-5), respectively, in a population aged 50 years or older. Relapses were frequent in both isolated PMR and PMR associated with GCA. In general, they occurred when the dose of prednisone was < 7.5 mg/day or it had been discontinued. Rate of steroid tapering was significantly higher in patients with isolated PMR who had relapses. Patients with HLA-DRB1*0401 had a higher frequency of relapses. As reported in patients with PMR associated with GCA, the adjusted mortality rate in patients with isolated PMR showed no difference compared to the Spanish population aged 50 years or older.
CONCLUSION: In Northwestern Spain, PMR is a nonfatal disease with a low incidence and frequent relapses. A possible influence of HLA-DRB1*04 alleles in the development of more severe disease, with greater tendency to relapses, is suggested.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app